menu
close
This website is intended for UK Healthcare Professionals only. Not a UK Healthcare Professional? Click here
menu
close
menu
close

The adverse event reporting information can be found by scrolling to the bottom of this page.

VEOZA (fezolinetant) is indicated for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause.1

VMS are also known as hot flushes* and night sweats.2

Moa banner
VEOZA is not a hormone

VEOZA is not a hormone

It is the first-in-class selective neurokinin 3 (NK3) receptor antagonist to be licensed. It blocks neurokinin B (NKB) binding on the kisspeptin/neurokinin B/dynorphin (KNDy) neuron, which is postulated to restore the balance in KNDy neuronal activity in the thermoregulatory centre of the hypothalamus1,3,4

Watch the MOA of VEOZA

How VEOZA disrupts hot flushes

Homeostasis

Homeostasis

KNDy neurons in the hypothalamus are inhibited by oestrogen and stimulated by the neuropeptide, NKB. This balance contributes to body temperature regulation.3

Menopause

Menopause

Oestrogen decline during menopause disrupts this balance with NKB. Unopposed, NKB signalling causes heightened KNDy neuronal activity.3 This triggers heat dissipation mechanisms, including vasodilation and sweating–VMS.3

Blocking NKB to reduce heat

Blocking NKB to reduce heat

VEOZA selectively binds to the NK3 receptor to block NKB.1 This action moderates NKB signalling and KNDy neuron activity, helping to restore thermoregulatory balance and better control VMS.1,3

moa image
moa page mobile
Resource
RESOURCE

View the MOA of VEOZA1,3

Quickly reference how VEOZA disrupts hot flushes.

Discover efficacy and safety in VEOZA clinical trials

Sign up for VEOZA updates and product information

*Hot flushes are also known as hot flashes.3
 

KNDy: kisspeptin/neurokinin B/dynorphin, MOA: mechanism of action, NK3: neurokinin 3, NKB: neurokinin B, ORα, oestrogen receptor alpha, VMS: vasomotor symptoms.


REFERENCES: 1. VEOZA Summary of Product Characteristics. 2. Thurston RC. Vasomotor symptoms. In: Crandall CJ, Bachman GA, Faubion SS, et al., eds. Menopause Practice: A Clinician’s Guide. 6th ed. Pepper Pike, OH: The North American Menopause Society, 2019:43-55. 3. Depypere H, Lademacher C, Siddiqui E, Fraser GL. Fezolinetant in the treatment of vasomotor symptoms associated with menopause. Expert Opin Investig Drugs 2021;30(7):681-94. 4. Jayasena CN, Comninos AN, Stefanopoulou E, et al. Neurokinin B administration induces hot flushes in women. Sci Rep (Epub) 02-16-2015.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Astellas Pharma Ltd. on 0800 783 5018.

MAT-GB-VEO-2024-00243. February 2025.